Cargando…
A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway: Anti-myeloma activity of a novel alkaloid in drug-resistant cells
Multiple myeloma (MM), the seco nd most common haematological malignancy, is currently incurable because patients often develop multiple drug resistance and experience subsequent relapse of the disease. This study aims to identify a potential therapeutic agent that can counter bortezomib (BTZ) resis...
Autores principales: | Zhang, Bibo, Li, Bo, Xie, Yongsheng, Chang, Shuaikang, Xu, Zhijian, Hu, Huifang, Chen, Gege, Zhang, Ting, He, Jun, Wu, Xiaosong, Zhu, Huabin, Lai, Weiming, Song, Dongliang, Lu, Ying, Jia, Xinyan, Zhu, Weiliang, Shi, Jumei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157528/ https://www.ncbi.nlm.nih.gov/pubmed/36815376 http://dx.doi.org/10.3724/abbs.2023014 |
Ejemplares similares
-
The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway
por: Wang, Yingcong, et al.
Publicado: (2023) -
A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe
por: Hu, Liangning, et al.
Publicado: (2020) -
Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma
por: Gao, Minjie, et al.
Publicado: (2017) -
DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2
por: Kong, Yuanyuan, et al.
Publicado: (2019) -
Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma
por: Feng, Qilin, et al.
Publicado: (2020)